To examine antihypertensive effect and safety of administration of CS-3150 in combination with ARB or ACE inhibitor in hypertensive patients with type 2 diabetes and albuminuria.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
51
CS-3150 1.25 to 2.5, 5mg, orally
Unnamed facility
Sanuki-shi, Kagawa-ken, Japan
Change from baseline in sitting systolic and diastolic blood pressure
Change from baseline in sitting systolic and diastolic blood pressure
Time frame: Baseline to end of Week 12
Time course of systolic and diastolic blood pressure
Time course of systolic and diastolic blood pressure
Time frame: Baseline to end of Week 12
Proportion of patients achieving blood pressure control
Proportion of patients achieving blood pressure control
Time frame: Baseline to end of Week 12
Change rate from baseline in urine-albumin-to-creatinine ratio
Change rate from baseline in urine-albumin-to-creatinine ratio.
Time frame: Baseline to end of Week 12
Time course of urine-albumin-to-creatinine ratio
Time course of urine-albumin-to-creatinine ratio.
Time frame: Baseline to end of Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.